Literature DB >> 8979405

Alterations of fibrinolytic activity in human during and after hyperbaric oxygen exposure.

N Yamami1, K Shimaya, A M Sera, H Fujita, M Shibayama, Y Mano, M Maruyama, H Mihara.   

Abstract

To clarify the stage of fibrinolytic activation by hyperbaric oxygen (HBO) exposure, we examined its alterations in human during and after the HBO exposure. Eight healthy female volunteers breathed oxygen at 284 kPa (2.8 atmospheres absolute). Blood samples were collected before compression, shortly after compression to the pressure 284 kPa, shortly before the start of decompression, shortly after decompression, and then again 3 hours after decompression. We estimated the euglobulin fibrinolytic activity (EFA) and, the activities and antigens of both tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1). The PAI-1 activity and PAI-1 antigen showed significant decrease after compression to a pressure 284 kPa, before the start of decompression, and after decompression. The EFA level and t-PA activity rose significantly shortly after decompression, and 3 hours later returned on baseline. These findings suggest that fibrinolytic activity is elicited after HBO rather than during HBO.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8979405     DOI: 10.2114/jpa.15.239

Source DB:  PubMed          Journal:  Appl Human Sci        ISSN: 1341-3473


  2 in total

1.  Hyperbaric oxygen therapy prevents coagulation disorders in an experimental model of multiple organ failure syndrome.

Authors:  Francesco Imperatore; Salvatore Cuzzocrea; Domenico De Lucia; Marcella Sessa; Barbara Rinaldi; Annalisa Capuano; Giovanni Liguori; Amelia Filippelli; Francesco Rossi
Journal:  Intensive Care Med       Date:  2006-09-15       Impact factor: 17.440

Review 2.  Co-administration of tissue plasminogen activator and hyperbaric oxygen in ischemic stroke: a continued promise for neuroprotection.

Authors:  Ze-Song Yang; Jun Mu
Journal:  Med Gas Res       Date:  2017-03-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.